BMY
Bristol-Myers Squibb Company Healthcare - Pharmaceuticals Investor Relations →
Bristol-Myers Squibb Company (BMY) closed at $54.00 as of 2026-06-19, trading 4.3% above its 200-week moving average of $51.77. The stock is currently moving closer to the line, down from 10.2% last week. The 14-week RSI sits at 38, indicating neutral momentum.
Trading volume is running at 1.4x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.81 ratio) is neutral — neither side is clearly dominating.
Over the past 2772 weeks of data, BMY has crossed below its 200-week moving average 29 times. On average, these episodes lasted 25 weeks. Historically, investors who bought BMY at the start of these episodes saw an average one-year return of +4.7%.
With a market cap of $110.3 billion, BMY is a large-cap stock. The company generates a free cash flow yield of 8.9%, which is notably high. Return on equity stands at 38.7%, indicating strong profitability. The stock trades at 5.5x book value.
Over the past 33.5 years, a hypothetical investment of $100 in BMY would have grown to $1265, compared to $3097 for the S&P 500. BMY has returned 7.9% annualized vs 10.8% for the index, underperforming the broader market over this period.
Free cash flow has been growing at a 2.4% compound annual rate, with 4 consecutive years of positive cash generation.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: BMY vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After BMY Crosses Below the Line?
Across 22 historical episodes, buying BMY when it crossed below its 200-week moving average produced an average return of -1.6% after 12 months (median +3.0%), compared to +8.3% for the S&P 500 over the same periods. 52% of those episodes were profitable after one year. After 24 months, the average return was -10.1% vs +14.2% for the index.
Each line shows $100 invested at the moment BMY crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices BMY would reach each dislocation threshold.
Dislocation Price Levels
Prices where BMY's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-07-30.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $54.08 | Unusually cheap — potential buy zone |
| Value | +1σ | $58.17 | Cheap vs. own history |
| Fair Value | +0σ | $62.94 | Historical mean behavior |
| Expensive | -1σ | $68.55 | Expensive vs. own history |
| Deep Expensive | -2σ | $75.27 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from BMY's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
BMY has crossed below its 200-week MA 29 times with an average 1-year return of +4.7% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| May 1973 | Jul 1973 | 9 | 11.7% | -16.5% | +19438.3% |
| Aug 1973 | Jan 1975 | 77 | 43.4% | -22.2% | +18600.1% |
| Feb 1978 | Mar 1978 | 3 | 3.3% | +16.7% | +17009.9% |
| Mar 1978 | Apr 1978 | 1 | 0.9% | +19.8% | +17009.9% |
| Oct 1978 | Oct 1978 | 1 | 2.8% | +9.2% | +16134.6% |
| Jul 1979 | Jul 1979 | 1 | 0.6% | +31.5% | +15155.3% |
| Mar 1980 | Mar 1980 | 3 | 2.3% | +83.2% | +15095.0% |
| Jan 1993 | Jan 1995 | 105 | 17.8% | +2.3% | +1154.9% |
| Jul 2000 | Aug 2000 | 5 | 1.4% | +14.0% | +199.5% |
| Sep 2000 | Sep 2000 | 1 | 0.2% | +16.4% | +190.2% |
| Apr 2001 | Jul 2001 | 13 | 8.4% | -43.3% | +165.1% |
| Sep 2001 | Sep 2001 | 1 | 7.3% | -51.0% | +174.7% |
| Oct 2001 | Nov 2001 | 2 | 3.9% | -50.8% | +162.9% |
| Nov 2001 | Feb 2006 | 220 | 60.4% | -48.9% | +159.4% |
| Aug 2006 | Aug 2006 | 3 | 10.7% | +48.3% | +460.5% |
| Jan 2008 | Dec 2008 | 47 | 22.5% | +3.3% | +364.0% |
| Jan 2009 | Jul 2009 | 28 | 17.9% | +20.1% | +355.9% |
| Oct 2016 | Nov 2016 | 4 | 6.6% | +34.7% | +51.6% |
| Jan 2017 | Feb 2017 | 5 | 12.5% | +29.9% | +52.2% |
| Mar 2017 | Jul 2017 | 18 | 4.0% | +19.5% | +37.8% |
| Apr 2018 | Jul 2018 | 15 | 11.3% | -8.3% | +41.7% |
| Oct 2018 | Oct 2019 | 54 | 21.1% | -7.2% | +24.3% |
| Mar 2020 | Mar 2020 | 2 | 9.7% | +33.7% | +41.8% |
| Jul 2023 | Aug 2023 | 3 | 1.9% | -13.8% | +0.1% |
| Sep 2023 | Nov 2024 | 63 | 33.0% | -16.0% | +1.1% |
| Dec 2024 | Jan 2025 | 6 | 2.8% | -1.4% | +3.9% |
| Feb 2025 | Feb 2025 | 3 | 5.3% | +14.5% | +0.8% |
| Mar 2025 | Dec 2025 | 37 | 19.4% | +13.2% | +3.6% |
| Dec 2025 | Jan 2026 | 1 | 0.2% | N/A | +3.3% |
| Average | 25 | — | +4.7% | — |
Frequently Asked Questions
Is BMY below its 200-week moving average?
No. Bristol-Myers Squibb Company (BMY) is currently 4.3% above its 200-week moving average of $51.77. It would need to fall to $51.77 to cross below the line.
What is BMY's 200-week moving average price?
Bristol-Myers Squibb Company's 200-week moving average is $51.77 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when BMY drops below its 200-week moving average?
BMY has crossed below its 200-week moving average 29 times in our data. On average, buying at that moment produced a one-year return of +4.7%. These dips have historically been decent entry points. These episodes lasted 25 weeks on average.
Is BMY a good value right now?
Here's what our data says about BMY as of 2026-06-19: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 38. Free cash flow yield is 8.9%. Return on equity is 38.7%. Price-to-book is 5.5x. This is not a buy or sell recommendation — always do your own research.
How does BMY compare to the S&P 500?
Over the past 33.5 years, $100 invested in BMY would have grown to $1265, compared to $3097 for the S&P 500. That's 7.9% annualized vs 10.8% for the index. BMY has underperformed the broader market over this period.
Does BMY pay a dividend?
Yes. Bristol-Myers Squibb Company currently pays a dividend yield of 451.00%.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19